Neurology internationalJul 27, 2026

New Treatment Approaches and Challenges for Major Brain Iron Accumulation Disorders

Longevity & Aging Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated Aug 3, 2026

Abstract

Neurodegeneration with brain iron accumulation (NBIA) encompasses rare genetic disorders marked by progressive neurological decline and abnormal iron buildup in the brain.

Iron accumulation is a common feature among NBIA disorders, yet most related genes do not directly affect iron metabolism.
Major forms of NBIA arise from disruptions in various cellular processes, including coenzyme A biosynthesis, lipid metabolism, mitochondrial function, and autophagy.
Preclinical approaches targeting CoA metabolism, mitochondrial function, lipid peroxidation, autophagy modulation, and genetic corrections have shown promising but not yet clinically validated results.
Challenges to clinical translation include the rarity of NBIA, clinical variability, lack of validated biomarkers, and preclinical models that inadequately mimic human disease.
Progress in the field may require earlier molecular diagnosis, development of biomarkers for disease tracking, and trial designs tailored to ultra-rare populations.
NBIA serves as a model for how understanding specific disease mechanisms can shift therapeutic strategies from focusing solely on shared imaging features.

Simplified

Neurodegeneration with brain iron accumulation (NBIA) comprises a group of rare genetic movement disorders characterized by progressive neurological deterioration, dystonia, parkinsonism, spasticity, and abnormal iron deposition in the basal ganglia. Although iron accumulation is the shared neuroradiological hallmark, most NBIA genes do not directly regulate iron metabolism. Instead, major NBIA forms arise from disruption of distinct but converging cellular pathways, including coenzyme A (CoA) biosynthesis, lipid metabolism, mitochondrial function, and autophagy. This narrative review aims to examine the pathogenic mechanisms of major NBIA disorders, namely pantothenate kinase-associated neurodegeneration (PKAN), COASY protein-associated neurodegeneration (CoPAN), PLA2G6-associated neurodegeneration (PLAN), mitochondrial membrane protein-associated neurodegeneration (MPAN), and beta-propeller protein-associated neurodegeneration (BPAN), and how these insights are guiding therapeutic development. Preclinical strategies aimed at restoring CoA metabolism, improving mitochondrial function, limiting lipid peroxidation, modulating autophagy, or correcting the underlying genetic defect have shown encouraging results, although none have yet reached robust clinical validation. Clinical translation remains limited by disease rarity, clinical heterogeneity, absence of validated biomarkers, and preclinical models that only partially recapitulate human pathology. Advancing the field will depend on earlier molecular diagnosis, biomarkers capable of tracking disease stage, and trial designs suited to ultra-rare populations. NBIA thus offers a paradigm for how mechanistic classification of a genetically defined disease group can redirect therapeutic strategy away from a shared radiological feature and toward pathway-specific intervention.

Full Text

Full text is available at the source.

View Full Text ↗

New Treatment Approaches and Challenges for Major Brain Iron Accumulation Disorders

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the longevity & aging brief